The application of multiple reaction monitoring to assess ApoA-I methionine oxidations in diabetes and cardiovascular disease

Translational Proteomics

Volumn 4-5, Issue , 2014, Pages 18-24

  Yassine, Hussein N ^a   Jackson, Angela M ^b   Reaven, Peter D ^c   Nedelkov, Dobrin ^d   Nelson, Randall W ^d   Lau, Serrine S ^e   Borchers, Christoph H ^b,f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF VICTORIA   (Canada)

^c CARL T HAYDEN VA MEDICAL CENTER   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f UNIVERSITY OF VICTORIA   (Canada)

Author keywords

Cardiovascular disease; Diabetes; HDL; Multiple reaction monitoring; Proteomics

Indexed keywords

EID: 84982061491     PISSN: 22129626     EISSN: 22129634     Source Type: Journal    
DOI: 10.1016/j.trprot.2014.10.001     Document Type: Article

References (17)

1. 1 Heidenreich, P.A., Trogdon, J.G., Khavjou, O.A., Butler, J., Dracup, K., Ezekowitz, M.D., Finkelstein, E.A., Hong, Y., Johnston, S.C., Khera, A., Lloyd-Jones, D.M., Nelson, S.A., Nichol, G., Orenstein, D., Wilson, P.W., Woo, Y.J., Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123:8 (2011), 933–944, 10.1161/CIR.0b013e31820a55f5 21262990.
2. 2 Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P.D., Zieve, F.J., Marks, J., Davis, S.N., Hayward, R., Warren, S.R., Goldman, S., McCarren, M., Vitek, M.E., Henderson, W.G., Huang, G.D., Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:2 (2009), 129–139, 10.1056/NEJMoa0808431 19092145.
3. 3 Gerstein, H.C., Miller, M.E., Byington, R.P., Goff, D.C. Jr., Bigger, J.T., Buse, J.B., Cushman, W.C., Genuth, S., Ismail-Beigi, F., Grimm, R.H. Jr., Probstfield, J.L., Simons-Morton, D.G., Friedewald, W.T., Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:24 (2008), 2545–2559, 10.1056/NEJMoa0802743 18539917.
4. 4 Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M., Marre, M., Cooper, M., Glasziou, P., Grobbee, D., Hamet, P., Harrap, S., Heller, S., Liu, L., Mancia, G., Mogensen, C.E., Pan, C., Poulter, N., Rodgers, A., Williams, B., Bompoint, S., de Galan, B.E., Joshi, R., Travert, F., Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:24 (2008), 2560–2572, 10.1056/NEJMoa0802987 18539916.
5. 5 Kontush, A., Chapman, M.J., Why is HDL functionally deficient in type 2 diabetes?. Curr Diab Rep 8:1 (2008), 51–59, 10.1007/s11892-008-0010-5 18366999.
6. 6 Shao, B., Cavigiolio, G., Brot, N., Oda, M.N., Heinecke, J.W., Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc Natl Acad Sci U S A 105:34 (2008), 12224–12229, 10.1073/pnas.0802025105 18719109.
7. 7 Calabresi, L., Franceschini, G., Lecithin: cholesterol acyltransferase, high-density lipoproteins, and atheroprotection in humans. Trends Cardiovas Med 20:2 (2010), 50–53, 10.1016/j.tcm.2010.03.007 20656215.
8. 8 Yassine, H., Borges, C.R., Schaab, M.R., Billheimer, D., Stump, C., Reaven, P., Lau, S.S., Nelson, R., Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes. Proteomics Clin Appl 7:7-8 (2013), 528–540, 10.1002/prca.201200028 23696124.
9. 9 Anderson, L., Hunter, C.L., Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics: MCP 5:4 (2006), 573–588, 10.1074/mcp.M500331-MCP200 16332733.
10. 10 Kuzyk, M.A., Smith, D., Yang, J., Cross, T.J., Jackson, A.M., Hardie, D.B., Anderson, N.L., Borchers, C.H., Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol Cell Proteomics: MCP 8:8 (2009), 1860–1877, 10.1074/mcp.M800540-MCP200 19411661.
11. 11 Wittes, J., Lakatos, E., Probstfield, J., Surrogate endpoints in clinical trials: cardiovascular diseases. Stat Med 8:4 (1989), 415–425, 10.1002/sim.4780080405 2727465.
12. 12 Carels, R.A., Darby, L.A., Cacciapaglia, H.M., Douglass, O.M., Reducing cardiovascular risk factors in postmenopausal women through a lifestyle change intervention. J Womens Health 13:4 (2004), 412–426, 10.1089/154099904323087105 15186658.
13. 13 Vaisar, T., Pennathur, S., Green, P.S., Gharib, S.A., Hoofnagle, A.N., Cheung, M.C., Byun, J., Vuletic, S., Kassim, S., Singh, P., Chea, H., Knopp, R.H., Brunzell, J., Geary, R., Chait, A., Zhao, X.Q., Elkon, K., Marcovina, S., Ridker, P., Oram, J.F., Heinecke, J.W., Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 117:3 (2007), 746–756, 10.1172/JCI26206 17332893.
14. 14 Addona, T.A., Abbatiello, S.E., Schilling, B., Skates, S.J., Mani, D.R., Bunk, D.M., Spiegelman, C.H., Zimmerman, L.J., Ham, A.J., Keshishian, H., Hall, S.C., Allen, S., Blackman, R.K., Borchers, C.H., Buck, C., Cardasis, H.L., Cusack, M.P., Dodder, N.G., Gibson, B.W., Held, J.M., Hiltke, T., Jackson, A., Johansen, E.B., Kinsinger, C.R., Li, J., Mesri, M., Neubert, T.A., Niles, R.K., Pulsipher, T.C., Ransohoff, D., Rodriguez, H., Rudnick, P.A., Smith, D., Tabb, D.L., Tegeler, T.J., Variyath, A.M., Vega-Montoto, L.J., Wahlander, A., Waldemarson, S., Wang, M., Whiteaker, J.R., Zhao, L., Anderson, N.L., Fisher, S.J., Liebler, D.C., Paulovich, A.G., Regnier, F.E., Tempst, P., Carr, S.A., Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 27:7 (2009), 633–641, 10.1038/nbt.1546 19561596.
15. 15 Francis, G.A., High density lipoprotein oxidation: in vitro susceptibility and potential in vivo consequences. Biochim Biophys Acta 1483:2 (2000), 217–235, 10.1016/S1388-1981(99)00181-X 10634938.
16. 16 Brock, J.W., Jenkins, A.J., Lyons, T.J., Klein, R.L., Yim, E., Lopes-Virella, M., Carter, R.E., Thorpe, S.R., Baynes, J.W., Increased methionine sulfoxide content of ApoA-I in type 1 diabetes. J Lipid Res 49 (2008), 847–855, 10.1194/jlr.M800015-JLR200 18202432.
17. 17 Borges, C.R., Rehder, D.S., Jensen, S., Schaab, M.R., Sherma, N.D., Yassine, H., Nikolova, B., Breburda, C., Elevated plasma albumin and apolipoprotein A-I oxidation under suboptimal specimen storage conditions. Mol Cell Proteomics: MCP 13:7 (2014), 1890–1899, 10.1074/mcp.M114.038455 24736286.